Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
  • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
  • C07D285/135—Nitrogen atoms

Definitions

• This invention relates to an improved method in the treatment of acne particularly pustular acne, and more particularly to the treatment of acne by means of an orally ingested thiadiazole, more particularly 2-p-rnethoxyb enzenesulfonamide-S-isobutyl- 1 ,3 ,4-thiadi azole.
• This object is achieved in the method of treating acne which comprises: selecting a human having acne; and feeding said human a therapeutically effective dose of 2-pmethoxybenzenesulfonamide-S-isobutyl-1,3,4-thiadiazole.
• the therapy consists in the ingestion, by the patient suffering from acne, of tablets containing the thiadiazole. Although doses of 2-3 grams per day of the thiadiazole may be safely used, effective doses will be in the range of 0.5-1.0 gram per day.
• a convenient form of treatment is the use of tablets containing from about 250 mg. to about 1000 mg. of the 2 p methoxybenzene sulfonamide-S-isobutyl-l,3,4-thiadiazole, with an especially convenient amount being 500 mg. of the thiadiazole per tablet. Preparation of such tablets is given below.
• the orange colors were dissolved in a granulating solution consisting of a 24% solution of gelatin and acacra in water.
• the thiadiazole was then granulated with 1.0 gm. of the colored starch, the amount of granulating solution originally used being suflicient to result in a dry granulation procedure.
• the balance of the starch, the sodium bicarbonate and the magnesium stearate were then intimately mixed therewith and the mixture was compressed into tablets.
• the proportions used were sufiicient to result in the preparation of 100 tablets, each weighing 620 mg. and containing 500 mg. of the thiadiazole.
• EXAMPLE ILL-CAPSULES In this case 50.0 gm. of 2-p-methoxybenzenesulfonamide-5-isobutyl-l,3,4-thiadiazole was intimately mixed with 1.0 gm. of a light mineral oil. 100 capsules each containing 500 mg. of the thiadiazole were then prepared by placing 510 mg. of that mixture into hard gelatin capsules.
• the method of treating acne which comprises orally administering to a human affected with acne a daily dose of 0.5-3.0 grams, in individual doses of 250-1000 mg. of 2 p methoxybenzenesulfonamide 5 isobutyl-l,3,4-thiadiazole.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (1)

Publications (1)

Family

ID=25310383

Family Applications (1)

Country Status (2)

Cited By (1)

• 1959
  • 1959-11-06 US US851271A patent/US3137620A/en not_active Expired - Lifetime
• 1960
  • 1960-08-05 FR FR835158A patent/FR146M/fr active Active

Non-Patent Citations (1)

Also Published As

Similar Documents